
Johnson & Johnson’s Imaavy granted FDA approval for rare autoimmune disease gMG
Johnson & Johnson (J&J) has received approval from the US Food and Drug Administration for its FcRn blocker Imaavy (nipocalimab-aahu) in generalised myasthenia gravis (gMG). The drug has been authorised to treat the rare autoimmune disease in …